+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Gastroparesis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region

  • PDF Icon

    Report

  • 209 Pages
  • March 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5948216
Description Jump to:
Global diabetic gastroparesis treatment market is poised for a significant upswing in the coming years, as highlighted by a comprehensive market analysis. With a projected Compound Annual Growth Rate (CAGR) of 5.1% from 2024 to 2031. This growth trajectory underscores a burgeoning demand for effective treatments against diabetic gastroparesis (DGP), a condition predominantly affecting individuals with Type-1 and Type-2 diabetes, particularly females with Type-2 diabetes.

Market Dynamics

The increasing prevalence of diabetes worldwide, coupled with a heightened focus on addressing the substantial unmet medical needs associated with diabetic gastroparesis, is propelling market growth. The availability of reimbursement options for in-patient hospital stays in developed countries further augments this trend. Enhanced accessibility to medications and an overall improvement in affordability are also contributing to the expansion of the market.

However, the market faces challenges such as the prevalent use of non-prescription drugs for symptom management, which may impede early diagnosis of the condition. Additionally, the lack of robust clinical evidence supporting the efficacy of prescription drugs and the premature termination of clinical trials pose significant hurdles to market growth.

Innovations and Trends

A key trend shaping the market landscape is the shift towards consumer-friendly pricing models for drugs and treatment devices, aiming to increase treatment uptake globally. Innovations in product offerings, along with creative marketing strategies employed by key market players, are expected to enhance market penetration and facilitate the entry of new treatment modalities.

Market Segmentation Insights

The global diabetic gastroparesis treatment market is segmented based on product type, disease indication, and distribution channel. Drugs as a product type dominate the market and are projected to continue leading in revenue generation, throughout the forecast period. The surgical treatment products segment is anticipated to witness a higher CAGR, attributed to the long-term relief these interventions offer.

Compensated gastroparesis dominates the disease indications market, poised for steady growth. Among distribution channels, hospital pharmacies lead the way, with e-commerce channels also witnessing increasing popularity.

Regional Outlook

North America leads the global market, with the fastest growth rate of CAGR anticipated during the forecast period, owing to advanced healthcare infrastructure and high awareness levels. The Asia Pacific region is identified as a highly attractive market, offering significant opportunities for drug manufacturers and investors, due to its high CAGR. The Middle East & Africa region, although accounting for a smaller share of the global market, is expected to witness a steady growth rate.

Key Players in the Market

Prominent companies such as Janssen Global Services, LLC, Salix Pharmaceuticals, Inc., Abbott Laboratories, Medtronic, C. R. Bard, Inc., Kimberly-Clark Corporation, Boston Scientific Corporation, Cardinal Health, Inc., Rhythm Pharmaceuticals, Inc., Evoke Pharma, and Alfa Wassermann SPA are leading the charge in developing and marketing diabetic gastroparesis treatments.

Market Segmentation

By Product Type

  • Drugs
  • Gastroprokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin
  • Surgical Treatment Products
  • Gastric Electrical Stimulation (GES) Devices
  • Percutaneous Endoscopic Gastrostomy (PEG) Kit
  • Parenteral Nutrition

By Region

  • North America Market
  • Latin America Market
  • Europe Market Value
  • APAC Market Value
  • MEA Market Value


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Diabetic Gastroparesis Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Price Analysis, 2018 - 2023
3.1. Global Average Price Analysis, by Product Type/ Disease Indication, US$ Per Unit, 2018 - 2023
3.2. Prominent Factor Affecting Hemoglobinopathy Prices
3.3. Global Average Price Analysis, by Region, US$ Per Unit
4. Global Diabetic Gastroparesis Market Outlook, 2018 - 2031
4.1. Global Diabetic Gastroparesis Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Drugs
4.1.1.1.1. Gastroprokinetic Agents
4.1.1.1.2. Antiemetic Agents
4.1.1.1.3. Botulinum Toxin
4.1.1.2. Surgical Treatment Products
4.1.1.2.1. Gastric Electrical Stimulation (GES) Devices
4.1.1.2.2. Percutaneous Endoscopic Gastrostomy (PEG) Kit
4.1.1.2.3. Parenteral Nutrition
4.2. Global Diabetic Gastroparesis Market Outlook, by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Compensated Gastroparesis
4.2.1.2. Gastric Failure
4.3. Global Diabetic Gastroparesis Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Private Clinics
4.3.1.3. Drug Stores
4.3.1.4. Retail Pharmacies
4.3.1.5. E-commerce
4.4. Global Diabetic Gastroparesis Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. North America
4.4.1.2. Europe
4.4.1.3. Asia Pacific
4.4.1.4. Latin America
4.4.1.5. Middle East & Africa
5. North America Diabetic Gastroparesis Market Outlook, 2018 - 2031
5.1. North America Diabetic Gastroparesis Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Drugs
5.1.1.1.1. Gastroprokinetic Agents
5.1.1.1.2. Antiemetic Agents
5.1.1.1.3. Botulinum Toxin
5.1.1.2. Surgical Treatment Products
5.1.1.2.1. Gastric Electrical Stimulation (GES) Devices
5.1.1.2.2. Percutaneous Endoscopic Gastrostomy (PEG) Kit
5.1.1.2.3. Parenteral Nutrition
5.2. North America Diabetic Gastroparesis Market Outlook, by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Compensated Gastroparesis
5.2.1.2. Gastric Failure
5.3. North America Diabetic Gastroparesis Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Private Clinics
5.3.1.3. Drug Stores
5.3.1.4. Retail Pharmacies
5.3.1.5. E-commerce
5.4. North America Diabetic Gastroparesis Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. U.S. Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
5.4.1.2. U.S. Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
5.4.1.3. U.S. Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
5.4.1.4. Canada Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
5.4.1.5. Canada Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
5.4.1.6. Canada Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Europe Diabetic Gastroparesis Market Outlook, 2018 - 2031
6.1. Europe Diabetic Gastroparesis Market Outlook, by Product Type, Value (US$Bn) and Volume (Million Units), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Drugs
6.1.1.1.1. Gastroprokinetic Agents
6.1.1.1.2. Antiemetic Agents
6.1.1.1.3. Botulinum Toxin
6.1.1.2. Surgical Treatment Products
6.1.1.2.1. Gastric Electrical Stimulation (GES) Devices
6.1.1.2.2. Percutaneous Endoscopic Gastrostomy (PEG) Kit
6.1.1.2.3. Parenteral Nutrition
6.2. Europe Diabetic Gastroparesis Market Outlook, by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Compensated Gastroparesis
6.2.1.2. Gastric Failure
6.3. Europe Diabetic Gastroparesis Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Private Clinics
6.3.1.3. Drug Stores
6.3.1.4. Retail Pharmacies
6.3.1.5. E-commerce
6.4. Europe Diabetic Gastroparesis Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Germany Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.2. Germany Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.3. Germany Diabetic Gastroparesis Market by End User, Value (US$Bn) and Volume (Million Units), 2018 - 2031
6.4.1.4. U.K. Diabetic Gastroparesis Market by Product Type, Value (US$Bn) and Volume (Million Units), 2018 - 2031
6.4.1.5. U.K. Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.6. U.K. Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.7. France Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.8. France Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.9. France Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.10. Italy Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.11. Italy Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.12. Italy Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.13. Turkey Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.14. Turkey Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.15. Turkey Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.16. Russia Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.17. Russia Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.18. Russia Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.19. Rest of Europe Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.20. Rest of Europe Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.1.21. Rest of Europe Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Asia Pacific Diabetic Gastroparesis Market Outlook, 2018 - 2031
7.1. Asia Pacific Diabetic Gastroparesis Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Drugs
7.1.1.1.1. Gastroprokinetic Agents
7.1.1.1.2. Antiemetic Agents
7.1.1.1.3. Botulinum Toxin
7.1.1.2. Surgical Treatment Products
7.1.1.2.1. Gastric Electrical Stimulation (GES) Devices
7.1.1.2.2. Percutaneous Endoscopic Gastrostomy (PEG) Kit
7.1.1.2.3. Parenteral Nutrition
7.2. Asia Pacific Diabetic Gastroparesis Market Outlook, by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Compensated Gastroparesis
7.2.1.2. Gastric Failure
7.3. Asia Pacific Diabetic Gastroparesis Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Private Clinics
7.3.1.3. Drug Stores
7.3.1.4. Retail Pharmacies
7.3.1.5. E-commerce
7.4. Asia Pacific Diabetic Gastroparesis Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. China Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.2. China Diabetic Gastroparesis Market by Disease Indication, Value (US$Bn) and Volume (Million Units), 2018 - 2031
7.4.1.3. China Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.4. Japan Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.5. Japan Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.6. Japan Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.7. South Korea Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.8. South Korea Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.9. South Korea Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.10. India Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.11. India Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.12. India Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.13. Southeast Asia Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.14. Southeast Asia Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.15. Southeast Asia Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.16. Rest of Asia Pacific Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.17. Rest of Asia Pacific Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.1.18. Rest of Asia Pacific Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Latin America Diabetic Gastroparesis Market Outlook, 2018 - 2031
8.1. Latin America Diabetic Gastroparesis Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Drugs
8.1.1.1.1. Gastroprokinetic Agents
8.1.1.1.2. Antiemetic Agents
8.1.1.1.3. Botulinum Toxin
8.1.1.2. Surgical Treatment Products
8.1.1.2.1. Gastric Electrical Stimulation (GES) Devices
8.1.1.2.2. Percutaneous Endoscopic Gastrostomy (PEG) Kit
8.1.1.2.3. Parenteral Nutrition
8.2. Latin America Diabetic Gastroparesis Market Outlook, by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Compensated Gastroparesis
8.2.1.2. Gastric Failure
8.3. Latin America Diabetic Gastroparesis Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Private Clinics
8.3.1.3. Drug Stores
8.3.1.4. Retail Pharmacies
8.3.1.5. E-commerce
8.4. Latin America Diabetic Gastroparesis Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Brazil Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.1.2. Brazil Diabetic Gastroparesis Market by Disease Indication, Value (US$Bn) and Volume (Million Units), 2018 - 2031
8.4.1.3. Brazil Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.1.4. Mexico Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.1.5. Mexico Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.1.6. Mexico Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.1.7. Argentina Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.1.8. Argentina Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.1.9. Argentina Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.1.10. Rest of Latin America Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.1.11. Rest of Latin America Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.1.12. Rest of Latin America Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Middle East & Africa Diabetic Gastroparesis Market Outlook, 2018 - 2031
9.1. Middle East & Africa Diabetic Gastroparesis Market Outlook, by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.1.1. Key Highlights
9.1.1.1. Drugs
9.1.1.1.1. Gastroprokinetic Agents
9.1.1.1.2. Antiemetic Agents
9.1.1.1.3. Botulinum Toxin
9.1.1.2. Surgical Treatment Products
9.1.1.2.1. Gastric Electrical Stimulation (GES) Devices
9.1.1.2.2. Percutaneous Endoscopic Gastrostomy (PEG) Kit
9.1.1.2.3. Parenteral Nutrition
9.2. Middle East & Africa Diabetic Gastroparesis Market Outlook, by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.2.1. Key Highlights
9.2.1.1. Compensated Gastroparesis
9.2.1.2. Gastric Failure
9.3. Middle East & Africa Diabetic Gastroparesis Market Outlook, by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.3.1. Key Highlights
9.3.1.1. Hospital Pharmacies
9.3.1.2. Private Clinics
9.3.1.3. Drug Stores
9.3.1.4. Retail Pharmacies
9.3.1.5. E-commerce
9.4. Middle East & Africa Diabetic Gastroparesis Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1. Key Highlights
9.4.1.1. GCC Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.2. GCC Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.3. GCC Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.4. South Africa Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.5. South Africa Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.6. South Africa Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.7. Egypt Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.8. Egypt Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.9. Egypt Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.10. Nigeria Diabetic Gastroparesis Market by Product Type, Value (US$Bn) and Volume (Million Units), 2018 - 2031
9.4.1.11. Nigeria Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.12. Nigeria Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.13. Rest of Middle East & Africa Diabetic Gastroparesis Market by Product Type, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.14. Rest of Middle East & Africa Diabetic Gastroparesis Market by Disease Indication, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.1.15. Rest of Middle East & Africa Diabetic Gastroparesis Market by End User, Value (US$ Bn) and Volume (Million Units), 2018 - 2031
9.4.2. BPS Analysis/Market Attractiveness Analysis
10. Competitive Landscape
10.1.Product Type vs Disease Indication Heatmap 10.2.Company Market Share Analysis, 2023 10.3.Competitive Dashboard
10.4.Company Profiles
10.4.1. Janssen Global Services, LLC
10.4.1.1. Company Overview
10.4.1.2. Product Portfolio
10.4.1.3. Financial Overview
10.4.1.4. Business Strategies and Development
10.4.2. Evoke Pharma
10.4.2.1. Company Overview
10.4.2.2. Product Portfolio
10.4.2.3. Financial Overview
10.4.2.4. Business Strategies and Development
10.4.3. Cardinal Health, Inc.
10.4.3.1. Company Overview
10.4.3.2. Product Portfolio
10.4.3.3. Financial Overview
10.4.3.4. Business Strategies and Development
10.4.4. Salix Pharmaceuticals, Inc.
10.4.4.1. Company Overview
10.4.4.2. Product Portfolio
10.4.4.3. Financial Overview
10.4.4.4. Business Strategies and Development
10.4.5. Alfa Wassermann SPA
10.4.5.1. Company Overview
10.4.5.2. Product Portfolio
10.4.5.3. Financial Overview
10.4.5.4. Business Strategies and Development
10.4.6. Abbott Laboratories
10.4.6.1. Company Overview
10.4.6.2. Product Portfolio
10.4.6.3. Financial Overview
10.4.6.4. Business Strategies and Development
10.4.7. Medtronic Plc.
10.4.7.1. Company Overview
10.4.7.2. Product Portfolio
10.4.7.3. Financial Overview
10.4.7.4. Business Strategies and Development
10.4.8. C. R. Bard, Inc.
10.4.8.1. Company Overview
10.4.8.2. Product Portfolio
10.4.8.3. Financial Overview
10.4.8.4. Business Strategies and Development
10.4.9. Rhythm Pharmaceuticals, Inc.
10.4.9.1. Company Overview
10.4.9.2. Product Portfolio
10.4.9.3. Financial Overview
10.4.9.4. Business Strategies and Development
10.4.10. Boston Scientific Corporation
10.4.10.1. Company Overview
10.4.10.2. Product Portfolio
10.4.10.3. Financial Overview
10.4.10.4. Business Strategies and Development
10.4.11. Kimberly-Clark Corporation
10.4.11.1. Company Overview
10.4.11.2. Product Portfolio
10.4.11.3. Financial Overview
10.4.11.4. Business Strategies and Development
11. Appendix
11.1.Research Methodology
11.2.Report Assumptions
11.3.Acronyms and Abbreviations

Companies Mentioned

  • Janssen Global Services, LLC
  • Evoke Pharma
  • Cardinal Health, Inc.
  • Salix Pharmaceuticals, Inc.
  • Alfa Wassermann SPA
  • Abbott Laboratories
  • Medtronic Plc.
  • C. R. Bard, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Boston Scientific Corporation
  • Kimberly-Clark Corporation

Methodology

Loading
LOADING...

Related Topics

Related Reports

Gastroparesis Drugs Market - Product Image

Gastroparesis Drugs Market

  • Report
  • 200 Pages
  • Global
From
Diabetic Gastroparesis (DGp) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Diabetic Gastroparesis (DGp) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Gastroparesis Drugs - Global Strategic Business Report - Product Image

Gastroparesis Drugs - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2024-2032 - Product Image

Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Gastroparesis Drugs Market by Drug Class, Indication, Sales Channel - Global Forecast 2025-2030 - Product Image

Gastroparesis Drugs Market by Drug Class, Indication, Sales Channel - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.